Okeke Ogwulu CB, Williams EV, Chu JJ, et al. - Researchers conducted the study for evaluating the cost‐effectiveness of mifepristone and misoprostol (MifeMiso) compared with misoprostol only for the medical management of a missed miscarriage. Between October 2017 and July 2019, 711 women aged 16‐39 years with ultrasound evidence of a missed miscarriage were recruited from 28 hospitals across the UK. The within‐trial analysis discovered that, on the basis of cost-effectiveness, MifeMiso intervention is likely to be recommended by decision-makers for the medical management of women who have had a missed miscarriage.